wire - news in brief



Results 251 - 300 of 2229.

Health - Administration - 11.09.2020
Coronavirus: No quarantine for persons entering from border regions
At its meeting on 11 September, the Federal Council decided on the quarantine rules for persons entering Switzerland from neighbouring countries: only those regions of neighbouring countries where th

Health - Administration - 10.09.2020

Health - Life Sciences - 08.09.2020
LifeTime - Researchers partner to improve European healthcare
LifeTime - Researchers partner to improve European healthcare
The FMI is a partner of the pan-European LifeTime initiative. In two publications, researchers involved with the initiative - including FMI group leader Susan Gasser - present a detailed roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual's lifetime.

Health - Pharmacology - 08.09.2020
"These results are crucial for the future corona vaccination strategy"
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.

Life Sciences - Health - 07.09.2020
How to identify new molecular glue degraders
How to identify new molecular glue degraders
Molecular glue degraders are a new class of drugs that work by facilitating an interaction between a disease-causing target protein and a ubiquitin ligase complex, tagging the target protein for degradation.

Pharmacology - Health - 07.09.2020
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale

Pharmacology - Health - 02.09.2020
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo

Pharmacology - Health - 30.08.2020
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer

Health - Environment - 28.08.2020
Experts collect information on risks of COVID-19 in wastewater
Experts collect information on risks of COVID-19 in wastewater
The review paper "Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic" was co-authored by 34 contributors from around the world. What was Eawag's contribution? Eberhard Morgenroth: For May 2020 I had been invited to participate in the "International Water Summit" at the Ben-Gurion University in Israel.

Pharmacology - Health - 26.08.2020
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.

Health - Life Sciences - 24.08.2020
Breast cancer: New way for tumor cells to escape self-destruction
Breast cancer: New way for tumor cells to escape self-destruction
In the body, so-called programmed cell death prevents cells with irreparable damage from surviving and turning into cancer cells. In the "EMBO Journal", researchers at the University of Basel's Biozentrum, report how a certain protein variant thwarts the self-destruction and thus promotes the growth of breast cancer cells.

Pharmacology - Health - 22.08.2020
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar + Mekinist in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg

Pharmacology - Health - 20.08.2020
FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros

Health - Life Sciences - 18.08.2020
UZH Introduces Five New University Research Priority Programs
The University of Zurich is introducing five new University Research Priority Programs focusing on equal opportunities, human reproduction, rare diseases, digital religions and basic principles of learning.

Pharmacology - Health - 17.08.2020
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o

Health - Life Sciences - 13.08.2020
IOR takes part in innovative project for real-time Covid-19 testing device
SARS-CoV-2 virus analysis involves complex procedures and requires long waiting times.

Pharmacology - Health - 11.08.2020

Life Sciences - Health - 11.08.2020
Wyss Center and Osypka announce collaboration
Wyss Center and Osypka announce collaboration
Pushing the boundaries of implantable neuro-device development Today the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland and OSYPKA AG/OSYPKA Medtec, Rheinfelden, Germany and Longmont,

Pharmacology - Health - 10.08.2020
FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants

Health - 06.08.2020
Preventive Measures against Heat Contribute to Health Protection
Preventive Measures against Heat Contribute to Health Protection
On behalf of the Federal Office of Public Health, the Swiss Tropical and Public Health Institute (Swiss TPH) analysed the health consequences of the hot and dry summer of 2019 and compared it to the hot summers of 2003, 2015 and 2018. The results were published this week in the report "Health effects of heat in Switzerland and the importance of prevention measures".

Pharmacology - Health - 05.08.2020
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1  

Pharmacology - Health - 04.08.2020
Novartis announces Kymriah meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate   Kymriah previously receive

Pharmacology - Health - 03.08.2020
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1   Modera

Health - Pharmacology - 29.07.2020
Novartis receives Piqray approval in Europe - the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care   Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.

Health - Life Sciences - 28.07.2020
Immunoprotein impairs Sars-Cov-2
An international team with researchers of the Institute of Virology and Immunology (IVI) of the University of Bern and the Swiss Federal Food Safety and Veterinary Office (FSVO) showed that an endogenous protein prevents the virus from fusing with host cells.

Health - Computer Science - 27.07.2020
CHF 12 million funding for cutting-edge surgical technology
CHF 12 million funding for cutting-edge surgical technology
Researchers at the University of Basel have a vision: an individually configurable robot will revolutionize surgical procedures and provide numerous benefits for patients.

Pharmacology - Health - 27.07.2020
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,

Health - Life Sciences - 22.07.2020